about
Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data.Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD.National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.National cohort study comparing severe medium-term urinary complications after robot-assisted vs laparoscopic vs retropubic open radical prostatectomy.Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery.Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based studyComparison of complications after transrectal and transperineal prostate biopsy: a national population-based studyComparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based StudyImpact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in EnglandIdentifying skeletal-related events for prostate cancer patients in routinely collected hospital dataPatient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in EnglandTreatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based StudyImputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions
P50
Q31154169-444950AA-484B-4803-B1B8-808649340D07Q33552577-8E3C117E-C8B8-4B5C-BD93-C804D276EF73Q47252997-E847E791-EDA0-4E03-9D8B-4A56B7295678Q50070197-FC7F8802-B566-4D38-B849-8B220CA9B2ACQ51717836-B1D04E8B-7A06-409D-A603-6027DDA3E4DFQ88720397-B68E391A-4D51-4006-A261-CBCEAFFB0AA2Q89988034-8B293F0E-18F9-4BD6-A585-2F41657B53FEQ90116136-88F4A65A-E4DC-4AE4-BF58-F7B45A652B6BQ90484306-622C00B2-0F88-4C8D-8977-058E1D43AB0BQ91246763-66B27CFF-8E34-43A7-AD35-D7F2A25BC481Q92374077-A3FC4673-BB68-4B6F-954C-DAB02BBB9B30Q92515578-D97459F5-5A80-49DE-9611-3CB565D376BFQ93274186-2CBA169A-E74D-4E35-BBF3-C000B997572D
P50
description
researcher (ORCID 0000-0002-9695-6052)
@en
name
Matthew Parry
@en
type
label
Matthew Parry
@en
prefLabel
Matthew Parry
@en
P31
P496
0000-0002-9695-6052